Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model

[1]  G. Petsko,et al.  Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain , 2012, Molecular Psychiatry.

[2]  G. Petsko,et al.  Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. , 2012, Journal of Alzheimer's disease : JAD.

[3]  H. Fillit,et al.  Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias , 2011, Alzheimer's Research & Therapy.

[4]  Ralph A. Nixon,et al.  Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.

[5]  P. Greengard,et al.  A small‐molecule enhancer of autophagy decreases levels of Aβ and APP‐CTF via Atg5‐dependent autophagy pathway , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Caccamo,et al.  Naturally Secreted Amyloid-β Increases Mammalian Target of Rapamycin (mTOR) Activity via a PRAS40-mediated Mechanism* , 2011, The Journal of Biological Chemistry.

[7]  M. Ohno,et al.  Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. , 2011, Brain : a journal of neurology.

[8]  Wei Zhao,et al.  Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease , 2011, Molecular Neurodegeneration.

[9]  D. Brat,et al.  Discovery of a Proneurogenic, Neuroprotective Chemical , 2010, Cell.

[10]  C. Altar,et al.  Cognition-Enhancing Properties of Dimebon in a Rat Novel Object Recognition Task Are Unlikely to Be Associated with Acetylcholinesterase Inhibition or N-Methyl-d-aspartate Receptor Antagonism , 2010, Journal of Pharmacology and Experimental Therapeutics.

[11]  H. Stenmark,et al.  Protein Secretion: Unconventional Exit by Exophagy , 2010, Current Biology.

[12]  Arlan Richardson,et al.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. , 2010, The Journal of biological chemistry.

[13]  Daniel J Klionsky,et al.  Mammalian autophagy: core molecular machinery and signaling regulation. , 2010, Current opinion in cell biology.

[14]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[15]  J. Corey-Bloom,et al.  A randomized, placebo-controlled trial of latrepirdine in Huntington disease. , 2010, Archives of neurology.

[16]  D. Holtzman,et al.  Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo , 2009, Molecular Neurodegeneration.

[17]  Michael J Marino,et al.  Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. , 2009, Biochemical pharmacology.

[18]  Keiji Tanaka,et al.  The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases. , 2009, Biochimica et biophysica acta.

[19]  D. Mann,et al.  Insoluble α-synuclein in alzheimer’s disease without lewy body formation , 2009, Neurotoxicity Research.

[20]  I. Bezprozvanny,et al.  Evaluation of Dimebon in cellular model of Huntington's disease , 2008, Molecular Neurodegeneration.

[21]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[22]  F. Marceau,et al.  Receptor-independent, vacuolar ATPase-mediated cellular uptake of histamine receptor-1 ligands: possible origin of pharmacological distortions and side effects. , 2008, Toxicology and applied pharmacology.

[23]  S. Schreiber,et al.  Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. , 2007, Nature chemical biology.

[24]  R. Nixon,et al.  Neuronal macroautophagy: from development to degeneration. , 2006, Molecular aspects of medicine.

[25]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Bahr,et al.  Potential Compensatory Responses Through Autophagic/Lysosomal Pathways in Neurodegenerative Diseases , 2006, Autophagy.

[27]  S. Bachurin,et al.  Dimebon improves learning in animals with experimental Alzheimer's disease , 2000, Bulletin of Experimental Biology and Medicine.

[28]  A. Tolkovsky,et al.  The Dynamics of Autophagy Visualised in Live Cells: from Autophagosome Formation to Fusion with Endo/lysosomes , 2005, Autophagy.

[29]  D. Mann,et al.  Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation. , 2005, Neurotoxicity research.

[30]  S. O. Bachurin,et al.  Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons , 2003, Bulletin of Experimental Biology and Medicine.

[31]  S. Turner,et al.  Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.

[32]  S. Bachurin,et al.  Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer , 2001, Annals of the New York Academy of Sciences.

[33]  S. Bachurin,et al.  in Culture and Block L-type Ca2+ Channels , 2001 .

[34]  J. Avruch,et al.  Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism* , 1998, The Journal of Biological Chemistry.

[35]  C. Glabe,et al.  Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.